Rituximab for childhood nephrotic syndrome: a follow-up study
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study follows children with nephrotic syndrome (a kidney condition causing swelling) who are being treated for the first time with rituximab. It aims to see how well the medication works long-term.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be under 18 years old.
- Your child must have a type of nephrotic syndrome that comes back often, needs steroids to stay controlled, or doesn't respond to steroids.
- This must be the first time your child receives rituximab for their nephrotic syndrome.
- Your child's nephrotic syndrome should not be caused by other conditions like lupus, IgA nephropathy, or hepatitis.
- Your child's kidney function must be good (estimated filtration rate at least 60 mL/min/1.73m²).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how rituximab affects immune cells in people with a type of kidney disease called membranous nephropathy. By studying blood samples, the researchers hope to understand why some people respond better to treatment, which could help guide future care.
This trial tests whether rituximab (an immune-targeting medicine) plus cyclosporine (another immune medicine) can better control protein leakage in the urine for people with idiopathic membranous nephropathy. It may help reduce long-lasting kidney damage risk when standard treatments like ACE inhibitor or ARB don’t control the protein level.
This trial tests a new medicine called zuberitamab for children who have just had their first episode of nephrotic syndrome and have responded well to steroids. The goal is to see if this medicine can help keep the disease from coming back, with fewer side effects than standard treatments.
This trial tests whether a drug called rituximab can help children with their first episode of nephrotic syndrome stay in remission longer. It is for children who have already responded to steroid treatment.
This study tests a new combination of two medicines (rituximab and a low dose of mycophenolate mofetil) to help children with active lupus nephritis (kidney inflammation from lupus). The goal is to see if combining these drugs works better and is safe for children.
This study compares two antibody medicines, obinutuzumab and rituximab, to prevent relapses of steroid-dependent or frequently relapsing nephrotic syndrome in children. It looks at whether one option works better and is safer, including infection risk.
Hear when a new Nephrotic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.